NRF for Traumatic Brain Injury
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to evaluate the effectiveness of NeuroResource Facilitation, a novel/innovative intervention, in reducing recidivism in offenders with brain injury (BI).
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications.
How is the treatment NeuroResource Facilitation (NRF) unique for traumatic brain injury?
NeuroResource Facilitation (NRF) is unique because it focuses on enhancing the body's natural protective mechanisms by activating the Nrf2 pathway, which helps increase the expression of genes that protect against oxidative damage after a traumatic brain injury. This approach is different from other treatments that may not specifically target these endogenous protective pathways.12345
What data supports the effectiveness of the treatment NeuroResource Facilitation (NRF) for Traumatic Brain Injury?
Who Is on the Research Team?
Maria Kajankova
Principal Investigator
Icahn School of Medicine at Mount Sinai
Are You a Good Fit for This Trial?
This trial is for English-speaking adults over 18 with a history of brain injury, who are returning to specific counties in the U.S. within six months of release from incarceration. They must show significant cognitive impairment on certain tests.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive specialized care management through NeuroResource Facilitation (NRF) both in prison and after release, with weekly to monthly meetings depending on resource needs.
Follow-up
Participants are monitored for recidivism and engagement with health/medical resources, productive activities, and community support.
What Are the Treatments Tested in This Trial?
Interventions
- NeuroResource Facilitation (NRF)
NeuroResource Facilitation (NRF) is already approved in United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Icahn School of Medicine at Mount Sinai
Lead Sponsor
Brain Injury Association of Pennsylvania
Collaborator